KUALA LUMPUR, Sept 8 (Bernama) -- Bursa Malaysia closed almost flat on Tuesday as buying interest rotated away from index heavyweights towards smaller-cap construction stocks, with sentiment affected by geopolitical uncertainty, said an analyst. At 5 pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) eased 0.39 of a point to 1,714.40 from Monday’s close of 1,714.79. The benchmark index opened 1.65 points lower at 1,713.14 and moved between 1,710.44 and 1,714.50 throughout the trading session. The broader market was almost evenly balanced, with decliners leading gainers 548 to 546, while 598 counters were unchanged, 1,107 were untraded and 25 were suspended. Turnover expanded to 4.13 billion units valued at RM3.14 billion from 3.60 billion units valued at RM2.45 billion on Monday.
Stock up 9.6% — here's why investors are buzzing
Breakthrough Spotlight:
$Recursion Pharmaceuticals (RXRX.US)$ surged Monday after a WIRED article spotlighted REC-3565, an AI-designed MALT1 inhibitor drug showing promising early signs in fighting blood cancer. Developed using Recursion’s cutting-edge AI platform, this molecule is something “humans couldn’t have designed” through traditional means, according to Peter Ray, Senior Director of Medicinal Chemistry.
What Makes This Different?
Only 136 molecules were tested to develop REC-617, thanks to AI—vs. thousands in conventional drug discovery
REC-3565 is now in Phase 1 trials for relapsed leukemia and B-cell lymphoma
Ray believes this is just the start:
“Each drug we develop makes the next 10 even better.”
Why Investors Care:
AI speeds up R&D and slashes costs
Real-life patient in REC-617 trial showed miraculous recovery signs
Market sees Recursion leading the next-gen “TechBio revolution”
Big Picture:
Recursion’s merger with Exscientia not only brought new drugs but also amplified its AI capabilities. Greenwood's article paints a vivid future where drug discovery gets faster, smarter, and more humane.
Comments
Post a Comment